Abstract : Osaka University and Nippi Inc., a Japanese biotech company having an expertise in collagen and collagen-related products, succeeded in manufacturing laminin-511 E8 fragment, very potent cell-adhesive substrates for cultivation of human pluripotent stem cells, in accordance with GMP (good manufacturing practice). The laminin fragment, commercialized from Nippi under the trade name of “iMatrix-511 MG,” is suitable for production of clinical-grade human iPS cells and other stem cells in cell transplantation therapy. The new product will be commercially available in June 2015. iMatrix-511 GM will accelerate the production of a wide variety of pluripotent stem cells, particularly iPS cells, to be used in regenerative medicine.

Related link

• Laboratory of Extracellular Matrix Biochemistry, Institute for Protein Research, Osaka University